Duligotuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Duligotuzumab
Accession Number
DB12142
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MEHD7945A
Categories
UNII
8PMF8YQX2T
CAS number
1314238-96-4

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Duligotuzumab.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Duligotuzumab.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Duligotuzumab.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Duligotuzumab.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Duligotuzumab.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Duligotuzumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Duligotuzumab.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Duligotuzumab.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Duligotuzumab.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Duligotuzumab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Duligotuzumab.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Duligotuzumab.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Duligotuzumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Duligotuzumab.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Duligotuzumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Duligotuzumab.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Duligotuzumab.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Duligotuzumab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Duligotuzumab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Duligotuzumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Duligotuzumab.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Duligotuzumab.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Duligotuzumab.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Duligotuzumab.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Duligotuzumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Duligotuzumab.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Duligotuzumab.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Duligotuzumab.Experimental
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Duligotuzumab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Duligotuzumab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Duligotuzumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Duligotuzumab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Duligotuzumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Duligotuzumab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Duligotuzumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Duligotuzumab.Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Duligotuzumab.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Duligotuzumab.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Duligotuzumab.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911288

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentEpithelial Tumors, Malignant1
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentNeoplasms1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentHead and Neck Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:27 / Updated on November 06, 2017 06:46